[ad_1]
The annual conference of the American Diabetes Association (ADA) dominated the headlines of medical research this weekend, while pharmaceutical and biotechnology companies unveiled the latest data on therapies for type 2 disease.
Major manufacturers of diabetes medications and insulins such as Sanofi, Eli Lilly and Novo Nordisk are trying to produce data that will differentiate their products in an increasingly competitive market where there is an urgent need to justify prices, particularly to United States.
At this year's San Francisco conference, Sanofi published the results of the BRIGHT study comparing Toujeo (insulin glargine injection) with its long-time competitor, Tresiba (insulin degludec ).
The results showed that Toujeo had resulted in a greater improvement in glycemic control (HbA1c) compared to Tresiba (-1.72% vs. -1.30%, respectively), with no difference in incidence or rate of events of hypoglycemia confirmed in adults of type 2. Diabetes and moderate to severe impairment of renal function.
The findings are significant, Novo Nordisk highlighting the benefits of its insulin degludec (Tresiba) as a way to reduce the risk of hypoglycemia, as well as the badociated health risks.
There was also a lot of activity in the GLP-1 clbad, where Novo Nordisk and Eli Lilly compete with Ozempic (semaglutide) and Trulicity (dulaglutide), respectively, injected weekly.
Novo has already produced data from its PIONEER 2 and 4 studies on its oral formulation of semaglutide, while PIONEER 6 is expected to provide more data later this week.
In PIONEER 2, 14 mg of oral semaglutide showed a higher reduction in blood glucose of 1.3% compared to a reduction of 0.9% with empagliflozin 25 mg for the main parameter at 26 weeks and a reduction of statistically significant blood glucose for the secondary endpoint at 52 weeks.
PIONEER 4 showed that oral semaglutide was as effective as the daily injection of GLP-1 Victoza (liraglutide) in reducing blood sugar levels, while outperforming placebo.
Novo announced in November that its PIONEER 6 study comparing oral semaglutide to placebo, in addition to standard treatment, had met its primary endpoint, namely non-inferiority of major adverse cardiovascular events (MACE) compared with at the placebo.
A 21% reduction in MACE compared to placebo was not significant, but Novo will release detailed data later this week.
Eli Lilly published detailed results from REWIND, Trulicity's cardiovascular outcome test, which showed a significant 12% reduction in MACE. REWIND data showed a consistent MACE 3 effect in people with and without cardiovascular disease.
Lilly has also published interim data from several studies on its tirzépatide, an agonist of GIP and GLP-1 receptors, including improvements in markers of beta cell function and susceptibility to cell death. insulin.
After eight weeks of treatment, Japanese people with type 2 diabetes significantly reduced their blood sugar and body weight and improved the markers of non-alcoholic steatohepatitis (NASH), liver inflammation, and cell damage. by liver fat in people with type 2 diabetes.
Source link
